Cited by 1,575Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Open access

Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1533209100PMC PMC166236

Open this paper in CoChat — free account

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.

Integrity signals

Registry

Crossref · 10.1073/pnas.1533209100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Show all 38 references

Research works printed but not linked: 4

Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.

Sorted by citations

Items 201–300 of 1,000

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M. S., Bogle, D., Yan, L. E., Targan, S., Solomon, J. C., Nichol, G. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 200
Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Kwong, B., Gai, S. A., Elkhader, J. A., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 199
Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners
Teulings, H. E., Overkamp, M., Ceylan, E., Nieuweboer‐Krobotová, L., Bos, J. D., Nijsten, T. E. C., Wolkerstorfer, A., Luiten, R. M., & van der Veen, J. P. W. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12111 · Cited by 192
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity
Kim, R., Emi, M., & Tanabe, K. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02430.x · Cited by 195
The ABCs of artificial antigen presentation
Kim, J. V., Latouche, J., Rivière, I., & Sadelain, M. (2004) · Nature Biotechnology · doi:10.1038/nbt955 · Cited by 195
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype
Weng, W., Czerwinski, D. K., Timmerman, J. M., Hsu, F. J., & Levy, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.003 · Cited by 194
Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., & Sherry, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1507 · Cited by 190
Self-citation
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., Wang, P., Venkataramanan, R., Fan, J., Xie, W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13443 · Cited by 192
Regulatory T Cells and Human Disease
Cools, N., Ponsaerts, P., Tendeloo, V. F. V., & Berneman, Z. N. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/89195 · Cited by 194
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 195
The New B7s: Playing a Pivotal Role in Tumor Immunity
Flies, D. B., & Chen, L. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802e085a · Cited by 192
How tumours escape mass destruction
Stewart, T. J., & Abrams, S. I. (2008) · Oncogene · doi:10.1038/onc.2008.268 · Cited by 194
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., BUSAM, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 186
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
de Coaña, Y. P., Choudhury, A., & Kiessling, R. W. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.005 · Cited by 187
Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4
Goldstein, B. L., Gedmintas, L., & Todd, D. J. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38282 · Cited by 185
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza‐Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Gene-based vaccines and immunotherapeutics
Liu, M., Acres, B., Balloul, J., Bizouarne, N., Paul, S., Slos, P., & Squiban, P. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404845101 · Cited by 182
Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins
Dimitriou, I. D., Clemenza, L., Scotter, A. J., Chen, G., Guerra, F. M., & Rottapel, R. K. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00659.x · Cited by 182
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling
Evel-Kabler, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26169 · Cited by 180
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Ellis, S. R., Vierra, A. T., Millsop, J. W., Lacouture, M. E., & Kiuru, M. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.105 · Cited by 183
TGF-β, EMT, and resistance to anti-cancer treatment
Wang, X., Eichhorn, P. J. A., & Thiery, J. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.004 · Cited by 187
Immunology beats cancer: a blueprint for successful translation
Pardoll, D. M. (2012) · Nature Immunology · doi:10.1038/ni.2392 · Cited by 182
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns
Miyara, M., & Sakaguchi, S. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2010.137 · Cited by 181
Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity
Kocak, E., Lute, K. D., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D. G., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Houot, R., & Levy, R. (2008) · Blood · doi:10.1182/blood-2008-07-170274 · Cited by 181
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Du, Z., Abedalthagafi, M., Aizer, A. A., McHenry, A., Sun, H. H., Bray, M., Viramontes, O., Machaidze, R., Brastianos, P. K., Reardon, D. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3082 · Cited by 176
Humanized mouse model supports development, function, and tissue residency of human natural killer cells
Herndler‐Brandstetter, D., Shan, L., Yao, Y., Stecher, C., Plajer, V., Lietzenmayer, M., Strowig, T., de Zoete, M. R., Palm, N. W., Chen, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705301114 · Cited by 180
Advances in immunotherapy delivery from implantable and injectable biomaterials
Leach, D. G., Young, S. W., & Hartgerink, J. D. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.016 · Cited by 180
CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy
Kretz-Rommel, A., Qin, F., Dakappagari, N. K., Ravey, E. P., McWhirter, J. R., Oltean, D. I., Frederickson, S., Maruyama, T., Wild, M. A., Nolan, M. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5595 · Cited by 175
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 179
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 174
Vitiligo, reactive oxygen species and T-cells
Glassman, S. J. (2010) · Clinical Science · doi:10.1042/cs20090603 · Cited by 175
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
Hryniewicz, A., Boasso, A., Edghill‐Smith, Y., Vaccari, M., Fuchs, D., Venzon, D. J., Nacsa, J., Betts, M. R., Tsai, W.-P., Héraud, J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-010637 · Cited by 173
Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., & Bigner, D. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.04.001 · Cited by 173
Autoimmunity associated with immunotherapy of cancer
Amos, S. M., Duong, C. P. M., Westwood, J. A., Ritchie, D. S., Junghans, R. P., Darcy, P. K., & Kershaw, M. H. (2011) · Blood · doi:10.1182/blood-2011-01-325266 · Cited by 171
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells
Boasso, A., Herbeuval, J., Hardy, A. W., Winkler, C., & Shearer, G. M. (2004) · Blood · doi:10.1182/blood-2004-06-2089 · Cited by 171
Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anticalins’
Schlehuber, S., & Skerra, A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03294-5 · Cited by 170
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Genomic landscape of DNA repair genes in cancer
Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 174
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 171
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
Hodi, F. S., Oble, D. A., Drappatz, J., Velázquez, E. F., Ramaiya, N. H., Ramakrishna, N. R., Day, A. L., Kruse, A., Rae, S. M., Hoos, A., et al. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1183 · Cited by 166
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo
Powell, D. J., Felipe-Silva, A., Merino, M. J., Ahmadzadeh, M., Allen, T., Levy, C. L., White, D. E., Mavroukakis, S. A., Kreitman, R. J., Rosenberg, S. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4919 · Cited by 169
Self-citation
Drugs and autoimmunity – A contemporary review and mechanistic approach
Chang, C. C.-C., & Gershwin, M. E. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.012 · Cited by 165
Mannose receptor-targeted vaccines
Keler, T., Ramakrishna, V., & Fanger, M. W. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.12.1953 · Cited by 164
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 166
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger, Y. M., & Wolchok, J. D. (2008) · PubMed Central · Cited by 164
Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Sun, T., Zhou, Y., Yang, M., Hu, Z., Tan, W., Han, X., Shi, Y., Yao, J., Guo, Y., Yu, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0806 · Cited by 167
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 170
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 164
Spontaneous tumor rejection by cbl-b –deficient CD8+ T cells
Loeser, S., Loser, K., Bijker, M. S., Rangachari, M., van der Burg, S. H., Wada, T., Beissert, S., Melief, C. J. M., & Penninger, J. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061699 · Cited by 161
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gómez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 162
Antitumor Immunity and Cancer Stem Cells
Schatton, T., & Frank, M. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04568.x · Cited by 161
Vitiligo puzzle: the pieces fall in place
Westerhof, W., & d’Ischia, M. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00399.x · Cited by 161
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Tarhini, A. A., Lo, E., & Minor, D. R. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0865 · Cited by 159
Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma
Robinson, M. R., Chan, C. C., Yang, J. C.-H., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159
Self-citation
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 160
Advances in immunotherapy for melanoma
Redman, J. M., Gibney, G. T., & Atkins, M. B. (2016) · BMC Medicine · doi:10.1186/s12916-016-0571-0 · Cited by 165
Autoimmune Etiology of Generalized Vitiligo
Poole, I. C. L., & Luiten, R. M. (2008) · KARGER eBooks · doi:10.1159/000131485 · Cited by 158
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Yin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157
Cancer Immunotherapy
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 166
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
O’Mahony, D., Morris, J. C., Quinn, C., Gao, W., Wilson, W. H., Gause, B. L., Pittaluga, S., Neelapu, S. S., Brown, M. R., Fleisher, T. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1974 · Cited by 154
Self-citation
Establishing risk of human experimentation with drugs: lessons from TGN1412
Kenter, M., & Cohen, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69562-7 · Cited by 153
Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
Leclerc, M., Voilin, E., Gros, G., Corgnac, S., de Montpréville, V., Validire, P., Bismuth, G., & Mami‐Chouaib, F. (2019) · Nature Communications · doi:10.1038/s41467-019-11280-z · Cited by 155
Design and development of synthetic peptide vaccines: past, present and future
Bijker, M. S., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.4.591 · Cited by 152
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 158
Ipilimumab
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 152
α-CTLA-4 mAb-associated Panenteritis
Oble, D. A., Mino-Kenudson, M. A., Goldsmith, J. D., Hodi, F. S., Seliem, R. M., Dranoff, G., Mihm, M. C., Hasserjian, R. P., & Lauwers, G. Y. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817150e3 · Cited by 151
Defining the critical hurdles in cancer immunotherapy
Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., Atkins, M. B., Bartůňková, J., Bergmann, L., Berinstein, N. L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-214 · Cited by 154
Self-citation
Harnessing the Power of the Immune System to Target Cancer
Lizee, G. A., Overwijk, W. W., Radvanyi, L. G., Gao, J., Sharma, P., & Hwu, P. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-112311-083918 · Cited by 154
Self-citation
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 151
Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
Loos, M., Giese, N. A., Kleeff, J. H., Giese, T., Gaida, M. M., Bergmann, F., Laschinger, M., Büchler, M. W., & Frieß, H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.056 · Cited by 151
Immune and molecular correlates in melanoma treated with immune checkpoint blockade
Byrne, E. H., & Fisher, D. E. (2017) · Cancer · doi:10.1002/cncr.30444 · Cited by 157
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 151
Supernatural T cells: genetic modification of T cells for cancer therapy
Kershaw, M. H., Teng, M. W. L., Smyth, M. J., & Darcy, P. K. (2005) · Nature reviews. Immunology · doi:10.1038/nri1729 · Cited by 150
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 151
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
Kleiner, D. E., & Berman, D. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2140-5 · Cited by 148
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 148
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 149
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L. (2017) · Immunotherapy · doi:10.2217/imt-2016-0138 · Cited by 147
CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns
Liu, Y., Chen, G.-Y., & Zheng, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.09.006 · Cited by 147
Depletion of CD4+CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer–Bearing Mice
Viehl, C. T., Moore, T. T., Liyanage, U. K., Frey, D. M., Ehlers, J. P., Eberlein, T. J., Goedegebuure, P. S., & Linehan, D. C. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9015-y · Cited by 151
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 146
Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
Reuben, J. M., Lee, B.-N., Li, C., Gómez-Navarro, J., Bozon, V. A., Parker, C. A., Hernandez, I. M., Gutiérrez, C., Lopez‐Berestein, G., & Camacho, L. H. (2006) · Cancer · doi:10.1002/cncr.21854 · Cited by 144
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
Tirapu, I., Huarte, E., Guiducci, C., Arina, A., Zaratiegui, M., Murillo, O., González, Á., Berasain, C., Berraondo, P., Fortes, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1681 · Cited by 146
Multiple Costimulatory Modalities Enhance CTL Avidity
Hodge, J. W., Chakraborty, M., Kudo‐Saito, C., Garnett‐Benson, C., & Schlom, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5994 · Cited by 138
Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
Piersma, S. J. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0066-7 · Cited by 140
An innately interesting decade of research in immunology
Germain, R. N. (2004) · Nature Medicine · doi:10.1038/nm1159 · Cited by 136
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 141
Cancer immunotherapy: breaking the barriers to harvest the crop
Pardoll, D. M., & Allison, J. P. (2004) · Nature Medicine · doi:10.1038/nm0904-887 · Cited by 135
Self-citation
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
Keler, T., Halk, E., Vitale, L. A., O’Neill, T., Blanset, D. L., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T. A., Lönberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134
Self-citation
Immunotherapy earns its spot in the ranks of cancer therapy
Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 134
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
Wolchok, J. D., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Schadendorf, D., de Pril, V., Heller, K. N., Chen, T., Ibrahim, R. A., et al. (2010) · PubMed Central · Cited by 133
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen
Tang, Y., Lou, J., Alpaugh, R. K., Robinson, M. K., Marks, J. D., & Weiner, L. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2815 · Cited by 135

Authors: Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
ORCID: Phan, Giao Q.
Yang, James C.
Sherry, Richard M.
Hwu, Patrick
Topalian, Suzanne L.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Steinberg, Seth M.
Allison, James P.
Davis, Thomas A.
Rosenberg, Steven A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-06-25
Volume: 100
Issue: 14
Pages: 8372-8377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1533209100
PMC: PMC166236
OpenAlex: W2134638467
Cited by: 1,575
References: 38
Citations by year: 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
FWCI: 46.70
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
MeSH terms: Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks